Abstract
HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
Filing date: Feb 2, 1994
Issue date: Jan 16, 1996
Inventors: Bruce A. Dressman, James E. Fritz, Marlys Hammond, William J. Hornback, Stephen W. Kaldor, Vincent J. Kalish, John E. Munroe, Siegfried H. Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
Assignee: Agouron Pharmaceuticals, Inc.
Primary Examiner: D. Margaret M. Mach
Download
What is claimed is:
1. A compound of the formula ##STR136## or a prodrug thereof or a pharmaceutically acceptable salt thereof.
2. A stereoisomer of the compound according to claim 1, which has the formula ##STR137## or a prodrug thereof or pharmaceutically acceptable salt thereof.
3. An essentially pure salt according to claim 2.
4. An essentially pure stereoisomer according to claim 2.
5. A compound of the formula ##STR138##
6. A stereoisomer of the compound according to claim 5, which has the formula ##STR139##
7. An essentially pure stereoisomer according to claim 6.
8. An essentially pure prodrug according to claim 2.